6990 — Sichuan Kelun-Biotech Biopharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- HK$102.28bn
- HK$97.44bn
- CNY1.93bn
Annual income statement for Sichuan Kelun-Biotech Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 32.3 | 804 | 1,540 | 1,933 |
| Cost of Revenue | ||||
| Gross Profit | 11.8 | 527 | 759 | 1,274 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 810 | 1,222 | 1,924 | 2,072 |
| Operating Profit | -777 | -419 | -383 | -139 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -890 | -567 | -468 | -143 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -890 | -616 | -574 | -267 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -890 | -616 | -574 | -267 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -890 | -616 | -574 | -267 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -4.12 | -2.84 | -2.53 | -1.2 |